Literature DB >> 33037161

Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.

Saurabh Mittal1.   

Abstract

Entities:  

Year:  2021        PMID： 33037161     DOI： 10.4103/ijdvl.IJDVL_671_19

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  4 in total

1.  Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.

Authors:  Y Lo; T-F Tsai
Journal:  Br J Dermatol       Date:  2019-08-20       Impact factor: 9.302

2.  IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.

Authors:  Shany Sherman; Efrat Solomon Cohen; Iris Amitay-Laish; Emmilia Hodak; Lev Pavlovsky
Journal:  Acta Derm Venereol       Date:  2019-07-01       Impact factor: 4.437

Review 3.  Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.

Authors:  James G Krueger; Patrick M Brunner
Journal:  Exp Dermatol       Date:  2017-12-29       Impact factor: 3.960

Review 4.  Psoriasis and comorbid diseases: Epidemiology.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.